drugset

drugset / Trial / NCT05908721

Study of CM310 in Patients With Allergic Rhinitis

NCT05908721 ↗

Phase 2 Completed 100 enrolled Keymed Biosciences Co.Ltd

NaSingle-groupOpen-labelTreatment

Summary

This study is a multicenter, single arm, open-label phase II clinical study mainly evaluating the safety of CM310 in patients with allergic rhinitis.

Timeline

Start: 2023-08-23
Primary completion: 2023-12-10
Completion: 2023-12-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CM310	Monoclonal antibody	—	Subcutaneous

Indications